Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.

@article{Hacke2009IntravenousDI,
  title={Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.},
  author={Werner Hacke and Anthony J. Furlan and Yasir Al-Rawi and Antoni Davalos and Jochen B. Fiebach and Franz Gruber and Markku Kaste and Leslie J Lipka and Salvador Pedraza and P A Ringleb and Howard A. Rowley and Dietmar Schneider and Lee H Schwamm and Joaquin Serena Leal and Mariola Soehngen and Phil A Teal and Karin Wilhelm-Ogunbiyi and Max Wintermark and Steven Warach},
  journal={The Lancet. Neurology},
  year={2009},
  volume={8 2},
  pages={141-50}
}
BACKGROUND Previous studies have suggested that desmoteplase, a novel plasminogen activator, has clinical benefit when given 3-9 h after the onset of the symptoms of stroke in patients with presumptive tissue at risk that is identified by magnetic resonance perfusion imaging (PI) and diffusion-weighted imaging (DWI). METHODS In this randomised, placebo-controlled, double-blind, dose-ranging study, patients with acute ischaemic stroke and tissue at risk seen on either MRI or CT imaging were… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 235 extracted citations

Similar Papers

Loading similar papers…